HF
HOWL icon

HRT Financial’s Werewolf Therapeutics HOWL Stock Holding History

HRT Financial’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,861
Closed -$14K – 4695
2026
Q1 		$14K Buy
+17,861
New +$12.2K ﹤0.01% 3601
2025
Q4 		– Sell
-39,859
Closed -$78K – 3525
2025
Q3 		$78K Sell
39,859
-2,621
-6% -$3.59K ﹤0.01% 2549
2025
Q2 		$46K Buy
+42,480
New +$43.7K ﹤0.01% 2318
2024
Q3 		– Sell
-197,377
Closed -$481K – 2726
2024
Q2 		$481K Buy
197,377
+159,749
+425% +$767K ﹤0.01% 1317
2024
Q1 		$243K Buy
+37,628
New +$219K ﹤0.01% 1664

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

HRT Financial's HOWL Position: Q2 2026 in Review

HRT Financial sold out of Werewolf Therapeutics (HOWL) in Q2 2026, closing a stake of 17,861 shares — an estimated $14K sold.

HRT Financial first reported a position in HOWL in Q1 2024 and held it in 5 quarters. The position peaked at $481K in Q2 2024. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • HRT Financial reported no remaining Werewolf Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 17,861 Werewolf Therapeutics shares in Q2 2026, an estimated $14K.
  • HRT Financial first reported a position in Werewolf Therapeutics in Q1 2024 and held it in 5 quarters.
  • HRT Financial's Werewolf Therapeutics position peaked at $481K in Q2 2024.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.